Keay Nakae
Stock Analyst at Chardan Capital
(4.37)
# 334
Out of 5,072 analysts
264
Total ratings
44.71%
Success rate
21.83%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALUR Allurion Technologies | Maintains: Neutral | $2.5 | $1.61 | +55.28% | 7 | Nov 20, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 | $57.71 | +3.97% | 21 | Nov 19, 2025 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 | $4.04 | +197.03% | 18 | Nov 17, 2025 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 | $4.41 | +13.38% | 14 | Nov 14, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $6.38 | +119.44% | 22 | Nov 14, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $87.36 | +14.47% | 6 | Nov 13, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $5.24 | +281.68% | 13 | Nov 13, 2025 | |
| KRRO Korro Bio | Downgrades: Neutral | $25 → $7 | $5.52 | +26.81% | 4 | Nov 13, 2025 | |
| RNA Avidity Biosciences | Maintains: Neutral | $72 | $71.56 | +0.61% | 21 | Nov 11, 2025 | |
| PRQR ProQR Therapeutics | Maintains: Buy | $4 | $2.34 | +70.94% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $6.84 | +411.70% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $400 | $445.12 | -10.14% | 14 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $38 | $21.17 | +79.50% | 13 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $1.20 | +316.67% | 5 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $16.87 | -64.43% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $4.16 | +381.35% | 14 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $3.14 | +91.08% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.99 | +707.67% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.65 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $17.37 | -65.46% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $4.70 | +7,985.11% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $11.05 | +397.74% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $3.86 | +159.07% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $19.08 | +358.60% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.18 | +1,001.69% | 3 | Feb 9, 2021 |
Allurion Technologies
Nov 20, 2025
Maintains: Neutral
Price Target: $2.5
Current: $1.61
Upside: +55.28%
Arrowhead Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $60
Current: $57.71
Upside: +3.97%
SAB Biotherapeutics
Nov 17, 2025
Maintains: Buy
Price Target: $12
Current: $4.04
Upside: +197.03%
Arbutus Biopharma
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.41
Upside: +13.38%
Coya Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $14
Current: $6.38
Upside: +119.44%
Monopar Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $100
Current: $87.36
Upside: +14.47%
Orchestra BioMed Holdings
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $5.24
Upside: +281.68%
Korro Bio
Nov 13, 2025
Downgrades: Neutral
Price Target: $25 → $7
Current: $5.52
Upside: +26.81%
Avidity Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $72
Current: $71.56
Upside: +0.61%
ProQR Therapeutics
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $2.34
Upside: +70.94%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $6.84
Upside: +411.70%
Aug 1, 2025
Maintains: Buy
Price Target: $325 → $400
Current: $445.12
Upside: -10.14%
Jul 29, 2025
Maintains: Buy
Price Target: $50 → $38
Current: $21.17
Upside: +79.50%
Jun 25, 2025
Maintains: Buy
Price Target: $5
Current: $1.20
Upside: +316.67%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $16.87
Upside: -64.43%
Apr 7, 2025
Maintains: Buy
Price Target: $20
Current: $4.16
Upside: +381.35%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $3.14
Upside: +91.08%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.99
Upside: +707.67%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.65
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $17.37
Upside: -65.46%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $4.70
Upside: +7,985.11%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $11.05
Upside: +397.74%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $3.86
Upside: +159.07%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $19.08
Upside: +358.60%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.18
Upside: +1,001.69%